Opendata, web and dolomites

BESG SIGNED

Bioengineered exosomes based approaches for the effective treatment of non-small cell lung cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BESG project word cloud

Explore the words cloud of the BESG project. It provides you a very rough idea of what is the project "BESG" about.

anti    gef    composition    cancer    gefitinib    cellular    imaging    lung    mechanism    reduce    engineered    principal    alcoholism    air    reticuloendothelial    action    former    acceptable    site    technologies    medicine    inhibitor    therapeutics    peptide    sirna    besg    patients    clearance    underlying    expectancy    predominant    endogenous    bypass    smoking    conjugation    proteins    spc24    abstract    payload    area    res    cell    difficult    models    origin    causes    exo    model    evade    nanotechnology    precision    era    loading    dosage    occupational    sites    nanovesicles    drug    exosomes    egfr    payloads    metastasis    stromal    small    nucleic    mesenchymal    release    clinical    acids    culture    simultaneously    membrane    career    life    immune    mscs    mechanisms    natural    xenograft    cells    pollution    carriers    drugs    trainings    nsclcs    pharmacokinetics    patient    biodistribution    world    recognition    hsp4    death    protein    acid    compliance    exposure    composing    exogenous    bioengineered    smokers    clinically   

Project "BESG" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 175˙572 €
 EC max contribution 175˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2020
 Duration (year-month-day) from 2020-10-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 175˙572.00

Map

 Project objective

ABSTRACT: Lung cancer is the principal cause of cancer-related death around the world and has become more predominant among former than current smokers. Smoking, alcoholism, air pollution, occupational exposure are among the main causes of non-small cell lung cancer (NSCLCs). It is difficult to simultaneously deliver therapeutics and nucleic acid to the target site. With the advancement of nanotechnology, a delivery system composing of cellular proteins which can bypass the reticuloendothelial system (RES) and have the ability to release payload at the specific target site is the necessity of the current era. Exosomes (Exo) are clinically acceptable, having protein membrane composition and the ability to deliver payload at specific target sites. Having endogenous origin, Exo evade immune recognition and clearance compared to exogenous nanovesicles. Exo are natural carriers of nucleic acids and they can be engineered to deliver siRNA as well as anti-cancer drugs. In this we propose the conjugation or covering of mesenchymal stromal cells (MSCs) derived exosomes with HSP4 peptide (target specific to NSCLCs) and loading them with Gefitinib (GEF), an EGFR inhibitor and SPC24 siRNA (target for NSCLCs and metastasis). The delivery of GEF and SPC24 siRNA using bioengineered exosomes (BESG) will reduce their dosage; improve patient compliance and life expectancy of patients. BESG will be evaluated for their uptake mechanisms and their mechanism of action in cell culture models of NSCLCs. BESG will specifically target the NSCLCs and release its payloads at cancer site. The underlying mechanisms, pharmacokinetics, biodistribution and anti-cancer activity will be evaluated in xenograft model of NSCLCs using advance imaging technologies. The BESG developed during this program will have a clinical potential and the trainings obtained through this program will help in career advancement in the area of drug delivery and precision medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BESG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BESG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

QuanToPol (2020)

Quantum Topological Polaritonics

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More